Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. This trade represents a 43.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Regulus Therapeutics Stock Performance

Shares of Regulus Therapeutics stock traded up $0.05 during trading hours on Wednesday, reaching $1.27. The company’s stock had a trading volume of 283,082 shares, compared to its average volume of 348,120. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79. The company’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.59. The stock has a market cap of $83.19 million, a P/E ratio of -1.19 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, sell-side analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Institutional Investors Weigh In On Regulus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the third quarter worth about $10,154,000. Point72 Asset Management L.P. acquired a new position in Regulus Therapeutics during the 3rd quarter valued at about $1,403,000. Bank of New York Mellon Corp bought a new position in Regulus Therapeutics in the 2nd quarter worth about $352,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $204,000. Finally, Tyche Wealth Partners LLC raised its holdings in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 95,694 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.